Intravenous flucloxacillin is one of the most frequently used high-dose penicillin therapies in hospitalized patients, forming the cornerstone treatment of invasive Staphylococcus aureus infection. Being a nonreabsorbable anion, flucloxacillin has been suggested to cause hypokalaemia, although the frequency and magnitude of this unwanted effect is unknown. In a retrospective cohort, we investigated the incidence and extent of hypokalaemia after initiation of intravenous flucloxacillin or ceftriaxone therapy. In total, 77 patients receiving flucloxacillin (62% male, mean age 70.5 years) and 84 patients receiving ceftriaxone (46% male, mean age 70.8 years) were included.
| INTRODUCTION
Intravenous flucloxacillin is one of the most frequently used high-dose penicillin therapies. Being a penicillinase-resistant β-lactam, flucloxacillin finds its main application in treatment of infections caused by penicillinase-producing organisms. Currently, it is the cornerstone treatment of invasive Staphylococcus aureus infection in the Netherlands. Generally, the penicillins are considered safe, except for allergic manifestations and rare renal inflammatory effects. However, even in the absence of gross renal failure, the use of penicillins among other classes of antibiotics is associated with changes in fluid and electrolyte balance, in particular hypokalaemia. 1 The first report of this phenomenon dates back half a century, when 6 patients were reported who were treated with massive sodium penicillin therapy of whom 3 developed a significant hypokalaemia. This decrease in serum potassium was not explained by other potassium-reducing factors and resolved after cessation of therapy. 2 Hypokalaemia is suggested to develop because penicillins act as nonreabsorbable anions, causing a transmembrane potential gradient in the cortical collecting duct that is negative on the luminal side, thus enhancing potassium secretion.
have warned us of hypokalaemia in a variety of penicillin classes [3] [4] [5] [6] , among which are flucloxacillin and related penicillinase-resistant penicillins. 7, 8 However, although the consequences of this potential side effect can be severe, the exact incidence and severity of hypokalaemia in flucloxacillin treatment is currently unknown. Hypokalaemia can cause muscle weakness, rhabdomyolysis, intestinal ileus, serious cardiac arrhythmias and death. It is considered a multifactorial condition, with several factors acknowledged to be of influence in the general inhospital populations, in particular kidney function and the use of kaliuretic diuretics. 9, 10 This study aimed to investigate the incidence of hypokalaemia in patients who receive intravenous high-dosed flucloxacillin therapy and identify patients that are particularly at risk of developing hypokalaemia during flucloxacillin treatment, guiding the clinician to patients in whom extra vigilance is needed.
| METHODS
The study was conducted at the Canisius Wilhelmina Hospital, Nijmegen, the Netherlands, and approved by the local ethical committee.
We retrospectively screened all adult patients admitted to our hospital from 2010 to 2015 who received intravenous flucloxacillin (≥6 g/day)
or ceftriaxone (2 g/day). Only patients that were normokalaemic at the start of therapy (defined as at least 1 serum potassium level of 3.3-4.7 mmol/l, the lower and upper levels of normal in the Canisius Wilhelmina Hospital at the time, and no serum potassium levels below or above this range documented in the 24 hours before to 24 hours after start of antibiotic therapy). Moreover, a follow-up potassium level had to be documented at 48-120 hours after initiation of antibiotic therapy. Patients were excluded if they had fewer than 48 consecutive hours of antibiotic treatment or received >1 antibiotic.
Patients were also excluded if they were admitted to the intensive 
| RESULTS
In total, 77 patients receiving flucloxacillin (62% male, mean age 70.5 years, range 32-96 years) and 84 patients receiving ceftriaxone (46% male, mean age 70.8 years, range 28-96 years) were included; both groups had similar potassium levels at baseline (mean 3.9 mmol/l, range 3.3-4.7 mmol/l). Men had slightly higher potassium levels than women at baseline (4.0 mmol/l vs 3.9 mmol/l, P < .05).
There were more men in the flucloxacillin group than in the ceftriaxone group (62% and 46%, P <.05). As expected, the indication for antibiotic treatment differed between those receiving ceftriaxone and flucloxacillin. In those receiving ceftriaxone, the top 3 diagnoses at admission were complicated urinary tract infection or urosepsis (32%), pneumonia (21%), and sepsis of unknown origin (19%). In those receiving flucloxacillin therapy, this was Staphylococcus aureus bacteraemia (35%), cellulitis or wound infections (23%), or
What is already known about this subject
• Intravenous flucloxacillin is one of the most frequently used high-dose penicillin therapies.
• Hypokalaemia has been described in penicillin treatment.
So far, only 7 cases of hypokalaemia in flucloxacillin treatment have been described in the literature.
What this study adds
• This study is the first to give a cross-sectional estimate on the incidence of hypokalaemia in patients receiving intravenous flucloxacillin.
• Patients receiving intravenous flucloxacillin are at considerable risk (over 40%) to develop hypokalaemia.
Women are at higher risk to develop hypokalaemia than men.
• In patients receiving intravenous flucloxacillin, frequent monitoring of potassium levels is warranted.
spondylodiscitis, arthritis or osteomyelitis (9% developed hypokalaemia compared to 18% of all men. In those receiving kaliuretic diuretics, the incidence of hypokalaemia was slightly higher to those not receiving these drugs, although this did not reach statistical significance (36% and 23%, respectively, P = .09). In a forward-entry stepwise logistic regression model, we found that next to antibiotic treatment (P < 10 −4 ), sex (P < .001) and potassium levels at baseline (P = .03) were associated with the occurrence of hypokalaemia; however, incorporating these variables only strengthened the regression coefficient between antibiotic treatment and hypokalaemia (β = −2,06).
In 76% of patients, potassium levels were lower after treatment than at baseline (P < 10 −7 for ceftriaxone, P < 10 −10 for flucloxacillin).
The decrease in potassium levels was larger in patients receiving flucloxacillin, with a mean decrease during antibiotic treatment of 
| DISCUSSION
Although hypokalaemia is described as a class-effect of the penicillins, the awareness of this effect among clinicians is low, and the extent of this electrolyte imbalance had previously not been investigated in detail. We studied the incidence and magnitude of hypokalaemia in hypokalaemia is most frequently associated with the use of loop-and thiazide diuretics, causing excessive renal potassium excretion. [10] [11] [12] In the current cohort we found an incidence of hypokalaemia in those using kaliuretic diuretics of 36%, which further underlines the strikingly high incidence of hypokalaemia of 42% in those on flucloxacillin treatment. Being a multifactorial condition, we also investigated 
Age, mean ± SD (y) 70.8 ± 14.2 70.5 ± 14.9 Ns
3.9 ± 0.38 3.9 ± 0.35 Ns
Diuretic treatment
• kaliuretic diuretic (%) 20% 34% P = .05
• potassium-sparing diuretic (%) (combined with kaliuretic diuretic) 1% 6% Ns MDRD >60 ml/min/1.73 m 2 (%) 51% 73% P < .01
MDRD, Modification of Diet in Renal Disease score.
patient factors that could modify the risk of hypokalaemia. Kidney function did not predict the occurrence of hypokalaemia. However, we only included patients with mildly to moderately impaired kidney function, and only 12 patients had an MDRD <40 ml/min/1.73 m 2 .
In contrast, female sex significantly predicted the risk of hypokalaemia and, in our cohort, 64% of all patients suffering from hypokalaemia after start of the antibiotic treatment was female. In several recent studies on dyskalaemia, hypokalaemia was also found to be more common in women than in men. 10 There are several potential limitations of this study. First, its retrospective nature makes that group differences in baseline characteristics could potentially influence our outcomes. More men were included in the flucloxacillin than ceftriaxone group, but since we found male sex to be protective for hypokalaemia, this does not explain our results. Kaliuretic diuretics were used slightly more often in patients who received intravenous flucloxacillin, but correcting for kaliuretic drug use did not change our results. Also, the mortality rate was higher in patients receiving flucloxacillin, which could indicate that these patients had more severe disease. However, correction for this factor did not alter our results, nor did these patients develop hypokalaemia more often than nondeceased patients. Second, we lack information on the exact severity of illness of the study subjects, as well as information on food intake and possible gastrointestinal potassium loss. Third, the retrospective nature of this study does not allow us to prove causality. However, from a mechanistic perspective it is plausible that hypokalaemia occurs more frequently in flucloxacillin than ceftriaxone therapy. Both β-lactam antibiotics, they are composed of a salt (most often sodium) and an attached nonreabsorbable anion that increases kaliuresis. 1 The amount of nonreabsorbable anion can be estimated by calculating the amount of molars of sodium present in the daily dose of antibiotic therapy; the same amount of anion is administered. Since flucloxacillin dosed ≥6 g/day contains at least twice the amount of nonreabsorbable anion present in ceftriaxone, it has the potential to cause more potassium secretion in the distal tubule. Another mechanism that has been suggested to contribute to the hypokalaemia observed in high-dosed penicillin administration is that of solute diuresis. Because of the high amount of sodium administered with intravenous fluids that accompany intravenous penicillin treatment, the flow rate in the cortical collecting duct is increased, as proportionally is the excretion of osmoles (including potassium). 13 Indeed, in a case series of patients that developed hypokalaemia during flucloxacillin therapy, the presence of a high urine chloride concentration and polyuria argued for a combined pathophysiology of nonreabsorbable anion effects as well as osmotic diuresis as causal factors in the extensive kaliuresis. 8 However, since the amount of sodium in high-dose flucloxacillin treatment does not differ much from ceftriaxone treatment when compared to daily sodium administration in the in-hospital setting, this is not likely to explain the differences found between ceftriaxone-and flucloxacillin-treated patients. For example, approximately 300 mg sodium is administered with flucloxacillin 6 g/day compared to approximately 160 mg in ceftriaxone 2 g/day, both neglectable compared to the amount of sodium administered with standard intravenous fluid therapy (2 l/day NaCL 0.9%, or 18 g sodium chloride per day). Future studies are necessary to establish the exact mechanism by which the strong potassium lowering effect of flucloxacillin is caused.
FIGURE 1
Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia. A, Hypokalaemia was more frequent in patients on flucloxacillin than ceftriaxone treatment. Most patients developing hypokalaemia were female. B, after treatment, serum potassium levels were lower in patients on flucloxacillin treatment than ceftriaxone treatment (mean, SD). C, Histogram showing the distribution of potassium levels during treatment and D, the change in potassium level during treatment. Δ delta, defined as change from baseline to follow-up; K + , potassium;
ns, nonsignificant
In conclusion, in patients treated with high-dosed intravenous flucloxacillin, hypokalaemia occurs with a strikingly higher incidence than in those treated with ceftriaxone. However, even in the latter, moderate to severe hypokalaemia is observed in 1 in 10 patients.
Therefore, frequent and standardized monitoring of potassium levels is warranted after start of intravenous antibiotic treatment in general, but in particular of intravenous flucloxacillin therapy.
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